Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer by Betts, Gareth et al.
ORIGINAL ARTICLE
Suppression of tumour-speciﬁc CD4
+ T cells by
regulatory T cells is associated with progression
of human colorectal cancer
Gareth Betts,
1 Emma Jones,
1 Syed Junaid,
1 Tariq El-Shanawany,
1 Martin Scurr,
1
Paul Mizen,
1 Mayur Kumar,
1 Sion Jones,
1 Brian Rees,
2 Geraint Williams,
3
Awen Gallimore,
1 Andrew Godkin
1
ABSTRACT
Background There is indirect evidence that T cell
responses can control the metastatic spread of
colorectal cancer (CRC). However, an enrichment of
CD4
+Foxp3
+ regulatory T cells (Tregs) has also been
documented.
Objective To evaluate whether CRC promotes Treg
activity and how this inﬂuences anti-tumour immune
responses and disease progression.
Methods A longitudinal study of Treg activity on
a cohort of patients was performed before and after
tumour resection. Speciﬁc CD4
+ T cell responses were
also measured to the tumour associated antigens
carcinoembryonic antigen (CEA) and 5T4.
Results Tregs from 62 preoperative CRC patients
expressed a highly signiﬁcant increase in levels of Foxp3
compared to healthy age-matched controls (p¼0.007),
which returned to normal after surgery (p¼0.0075).
CD4
+ T cell responses to one or both of the tumour
associated antigens, CEA and 5T4, were observed in
approximately two-thirds of patients and one third of
these responses were suppressed by Tregs. Strikingly, in
all patients with tumour recurrence at 12 months,
signiﬁcant preoperative suppression was observed of
tumour-speciﬁc (p¼0.003) but not control CD4
+ T cell
responses.
Conclusion These ﬁndings demonstrate that the
presence of CRC drives the activity of Tregs and
accompanying suppression of CD4
+ T cell responses to
tumour-associated antigens. Suppression is associated
with recurrence of tumour at 12 months, implying that
Tregs contribute to disease progression. These ﬁndings
offer a rationale for the manipulation of Tregs for
therapeutic intervention.
INTRODUCTION
Colorectal cancer (CRC) is the fourth most
commonly diagnosed cancer, with an estimated
500000 deaths per annum. Treatment involves
surgical excision of malignant bowel and local
lymph nodes. Histopathological staging of CRC
correlates with prognosis and determines whether
the patient receives postoperative chemotherapy.
Despite advances in preoperative imaging, surgical
technique and neoadjuvant chemotherapy,
approximately 40e50% of patients have disease
recurrence following potentially curative surgery,
highlighting the demand for better treatment.
One possibility is to utilise the host’s immune
system to target residual tumour after surgery.
Immunohistological staining has shown that a high
inﬁltration of T cells into colorectal tumours
correlates with an improved 5-year survival and
serves as a better predictor of prognosis than
conventional histopathological staging. These data
support the premise that cellular immunity can
eliminate residual malignant cells following
surgery.
1
In the case of tumours amenable to surgery,
strategies to enhance anti-tumour immunity may
complement surgical excision. The antigens 5T4
and carcinoembryonic antigen (CEA) are expressed
highly in CRCs, with low expression in normal
tissue, and hence represent excellent candidate
antigens for immunotherapy.
2e4 Naturally occur-
ring CD8
+ and to a lesser extent CD4
+ T cell
responses to these antigens have been observed in
both CRC patients and healthy controls.
5e8
< Additional ﬁgures and tables
are published online only. To
view these ﬁles please visit the
journal online (http://gut.bmj.
com/content/61/8.toc).
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Signiﬁcance of this study
What is already known on this subject?
< Inﬁltration of colorectal cancer (CRC) with
certain lymphocytes correlates with prognosis.
< Increased peripheral blood Foxp3
+ regulatory T
cell (Treg) frequencies are associated with
several carcinomas.
< An increase in the ratio of CD3
+ T cells:Tregs
within CRC has been associated with increased
disease free survival.
What are the new ﬁndings?
< The presence of CRC is associated with higher
expression levels of Foxp3 in Tregs. These Tregs
inhibit anti-tumour immune responses.
< Inhibition of anti-tumour immune responses prior
to resection is associated with tumour recur-
rence at 12 months. Excision of the primary CRC
leads to a normalisation of the Treg population.
How might it impact on clinical practice in the
foreseeable future?
< Targeting Tregs may offer an important thera-
peutic strategy as an adjunct to treatment of
patients.
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ColonAttempts to boost anti-tumour immunity have been disap-
pointing, with a low rate of objective responses to immuno-
therapy measured in clinical trials.
9 Research focused on
understanding why immunotherapeutic strategies fail indicates
that while Tcell responses can be effective at destroying tumour
cells, their efﬁcacy is limited by immunosuppressive inﬂuences.
A prominent candidate is a population of naturally occurring
regulatory T cells characterised by the surface expression of
CD4
+ and nuclear expression of the transcription factor Foxp3
(Tregs). Tregs play a key role in suppressing autoimmunity and
mutation of Foxp3 induces lethal immunopathology in
humans
10 and mice.
11 Many laboratories have shown that
a partial and transient depletion of Tregs is sufﬁcient to reject
transplanted tumour cell lines,
12 13 and reduce de novo tumour
development.
14 15 In humans, Tregs are often elevated in
patients with malignancies,
16 including CRC.
17 A recent report
suggests that the ratio of tumour intraepithelial effector CD3
+
T cells to Foxp3
+ T cells inﬂuences CRC patient prognosis.
18
Furthermore, it has been reported that Tregs from peripheral
blood of CRC patients can be stimulated with long synthetic
peptides derived from certain tumour antigens.
19
Investigations of the relationship between Tregs and cancer
have been largely observational and cross sectional in nature.
While useful, these studies omit potentially signiﬁcant infor-
mation relating to ﬂuctuations in Treg activity due to tumour
progression or treatment. To address this we examined anti-
tumour immune responses in CRC patients before and at
multiple time-points post-surgery, enabling us to speciﬁcally
address whether Tregs are inﬂuenced by the presence of tumour.
We also addressed whether the presence of tumour is associated
with suppression of tumour-speciﬁc immune responses. For
this purpose, CD4
+ T cell responses speciﬁc for the tumour-
associated antigens, CEA and 5T4, and control unrelated anti-
gens were analysed pre- and postoperatively in the same group
of patients, and the impact of Tregs on these responses was
analysed.
MATERIALS AND METHODS
Sample groups
Sixty-two CRC patients identiﬁed with the ﬁrst presentation of
an adenocarcinoma (TNM stage IIeIII; Duke’s stage AeC) and
no reported distant metastases were recruited to the study,
approved by the local research ethics committee. A breakdown of
the pre- and postoperative samples collected from these patients
and laboratory analysis of samples is indicated in individual
ﬁgures. Samples were collected from age-matched controls and
patients (age range 29e95) prior to surgery and then during
follow-up at 12 weeks, 6 months and 12 months. Clinical
details of patients who had surgery are provided in supplemen-
tary table 1.
Antigens
Puriﬁed protein derivative (PPD) (Statens Serum Institute,
Denmark), inﬂuenza haemagglutinin (HA; Dr John Skehel,
NIMR, UK), 5T4
20 (Oxford Biomedica, Oxford, UK) and carci-
noembryonic antigen (CEA; Calbiochem, Darmstadt, Germany),
were used at a ﬁnal concentration of 1 mg/ml.
Puriﬁcation of lymphocytes
Usually 30e50 ml of blood was drawn from patients or controls
and heparinised (10 U/ml). Peripheral blood mononuclear cells
(PBMCs) were extracted by centrifugation over Lymphoprep
(Axis-Shield, Oslo, Norway) and washed before further use.
Flow cytometric analysis of lymphocytes from blood
Frozen lymphocytes, taken at different time-points from
patients and controls, were thawed on the same day for
phenotypic analysis. Antibodies were as follows: CD4 APC
(clone M-T466), CD25 PE (clone 4E3) and CD3 APC (clone
BW264/56; Miltenyi Biotech, Auburn, California, USA); integrin
b7 PE (clone FIB504, BD PharMingen, San Diego, California,
USA), CD49d PE (clone 9F10) and Foxp3 FITC (clone PCH101;
eBioscience, San Diego, California, USA). Surface staining was
performed in phosphate buffered saline (PBS), 2.5% foetal calf
serum (FCS) and 5 mM EDTA. Flow cytometry was performed
on a BD FacsCalibur and analysed using FlowJo V.7.2.2.
Cognate CD4
+ T cell responses measured by ex-vivo
interferon-g ELISpot assay
Assays were performed as described previously.
17 Brieﬂy,
MAHA-S-4510 ELISpot Plates (Millipore, Moslheim, France)
were coated with an anti-interferon (IFN)-g antibody (Mabtech,
Nakta, Sweden) and washed in PBS. CD25
hi cells were depleted
from PBMC using magnetic separation with MACS CD25
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany).
PBMC (1.5310
7) were incubated with 15 ml of anti-CD25 coated
beads in total reaction volume of 150 ml of buffer (13PBS, 0.5%
bovine serum albumin (BSA), 5 mM EDTA) at 48C for 15 min.
An MS column was subsequently used and the efﬁcacy
of depletion conﬁrmed by ﬂow cytometry (supplementary
ﬁgure 1). Assays were set up using either 3.5310
5 undepleted or
CD25
hi-depleted cells in RPMI 1640 supplemented with 5%
heat-treated FCS, 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM L-glutamine and 1 mM sodium pyruvate per well in
a total reaction volume of 100 ml/well. Cells were subsequently
incubated in duplicate in 5% FCS with 1 mg/ml CEA, 5T4, PPD
and HA antigens or media alone. Following an 18-h incubation,
ELISpot plates were developed and spots were counted with an
automated plate reader. Responders were identiﬁed as having at
least ﬁve spot-forming cells (sfc) per 10
6 PBMC, after subtrac-
tion of the background, and an increase of at least 50% above
background as described before.
17 21 A response was considered
suppressed by Tregs if the number of sfc was at least 50% greater
after removal of the CD25
hi population.
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded human colorectal tumours
were obtained. Sections (5 mm) were cut and mounted on
Superfrost Plus slides (Thermo Scientiﬁc), dewaxed in xylene
and hydrated using graded alcohols to tap water. After
performing antigen retrieval by microwaving in 10 mM Tris,
1 mM EDTA buffer pH 9, sections were equilibrated in PBS.
Peroxidase activity was quenched with 1% hydrogen peroxide in
methanol, endogenous biotin was blocked using the
avidinebiotin kit (VectorLabs, Orton Southgate, Peterborough,
UK) and non-speciﬁc antibody binding was blocked by incu-
bating sections with 2.5% horse serum (VectorLabs). Samples
were then triple-stained by incubating sections sequentially
with antibodies against Foxp3 (clone PCH101; eBioscience),
CD8 (cloneC8/144B; DAKO, Glostrup, Denmark) and CD3
(clone UCHT1; DAKO) diluted in 1% BSA/PBS. Equivalent
concentrations of rabbit IgG and rat IgG2a were used as negative
control antibodies. Foxp3 was detected with biotinylated-anti-
rat followed by the Vectastain ABC kit (VectorLabs) and
visualised with DAB. CD8 was detected with anti-mouse/rabbit
Immpress (VectorLabs) and visualised using Vector VIP
(VectorLabs). CD3 was detected with anti-mouse/rabbit
Immpress (VectorLabs) and visualised using Vector SG
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Colon(VectorLabs). Sections were dehydrated and mounted in DPEX
(VWR, Lutterworth, Leicestershire, England). The number of
Foxp3 and CD3
+CD8
  (CD4
+) cells in 10 high power ﬁelds of
view was counted, and the percentage CD4
+ cells expressing
Foxp3 calculated. Photomicrographs were taken using a NIKON
microscope and digital camera.
Statistical analysis
Tests to examine differences between populations included
analyses of proportions (c
2 test and Fisher exact test), the non-
parametric Wilcoxon signal rank test on paired data, and the
Student t test on unpaired data. Statistical analyses used SPSS
V.11, Excel 2003 and GraphPad Prism V.4.
RESULTS
Evaluating the impact of CRC on CD4
+Foxp3
+ T cells
The ﬁrst question we sought to address was whether the pres-
ence of tumour impinges on the activity of Tregs. Thus, Tregs
from the blood of controls were compared with those of CRC
patients at pre- and postoperative time-points.
Analysis of FoxP3 expression in CRC patients and healthy controls
Tregs, identiﬁed as CD4
+CD25
hi cells, were examined by ﬂow
cytometry: CD3
+ peripheral blood leucocytes (PBL) were gated
and CD4
+CD25
hi Tregs were identiﬁed as CD3
+CD4
+ cells with
CD25 staining intensity above that observed in CD3
+CD4
  cells
(ﬁgure 1A) as described previously.
17 22 CD4
+Foxp3
+ cells were
gated (ﬁgure 1B) and the percentage of cells expressing Foxp3 in
the CD4
+CD25
hi,C D 4
+CD25
int and CD4
+CD25
  populations
was examined. The vast majority of Foxp3
+ cells resided in the
CD3
+CD4
+ population (>95%). Of 35 patients studied in this
way, 94% (65.7%) of the CD4
+CD25
hi population expressed
Foxp3 compared to 12% (65.7%) of CD4
+CD25
int cells and 1.3%
(60.96%) of CD4
+CD25
  cells (ﬁgure 1A); these frequencies were
comparable in healthy age matched controls (data not shown).
It is clear from our own observations and those of others that
Foxp3 expression levels correlate with suppressive capacity.
23
With this in mind, we examined the mean ﬂuorescent intensity
(MFI) of Foxp3 in our samples (ﬁgure 1C). We found, in
preoperative blood samples, that CD4
+CD25
hi cells expressed
signiﬁcantly higher levels of Foxp3 compared to the
CD4
+CD25
int cells, and a further reduction in expression levels
was identiﬁed in the small number of Foxp3
+ cells in the
CD4
+CD25
neg cell population (ﬁgure 1C). When Foxp3 expres-
sion levels were compared between CRC patients and healthy
controls, the level of Foxp3 expression was markedly higher in
the CRC group (ﬁgure 2A,B). This was observed when both the
CD25
hi population (p¼0.025, ﬁgure 2A) and the total CD4
+
population (p¼0.007, ﬁgure 2B) were compared. In keeping with
reports relating levels of Foxp3 expression to suppressor
activity,
24 these data imply an increase in the suppressive
capacity of Tregs in CRC patients compared to age matched
healthy controls.
Tregs are enriched within colorectal tumours
Immunohistochemistry identiﬁed striking inﬂuxes of Tregs into
the tumour. Most of these were found within the tumour
stroma and in association with other CD4
+ and CD8
+ T cells
(ﬁgure 3AeD). An analysis of over 40 tumours indicated that
Foxp3
+ cells reach an approximately equal ratio with CD4
+ T
cells, demonstrating a signiﬁcant enrichment of Tregs within the
tumour compared to PBMCs (ﬁgure 3E). High expression of
certain markers has been associated with Tregs that actively
migrate to sites of inﬂammation. Although the role of CD49d in
facilitating migration of Tcells to colorectal tumours has not, to
our knowledge, been elucidated, expression of this homing
receptor has been linked with recruitment of Tregs to inﬂamed
tissues and also with T cell inﬁltration of tumours in patients
Figure 1 Analysis of regulatory T cells (Tregs) in colorectal cancer
(CRC) patients. Peripheral blood mononuclear cells (PBMC) were stained
with CD3, CD4, CD25 and Foxp3 speciﬁc abs. CD3 gated cells were
examined for CD4 and CD25 expression (A) and CD4 and Foxp3
expression (B). The percentage of CD4
+CD25
hi, CD4
+CD25
int and
CD4
+CD25
  cells of total CD4
+ cells and proportion of each population
expressing Foxp3 is indicated (A). The MFI of Foxp3 expression on
CD4
+CD25
hi, CD4
+CD25
int and CD4
+CD25
  cells CD3
+CD4
+CD25
hi-
Foxp3
+ is shown (C).
Figure 2 Comparison of Foxp3
expression by regulatory T cells (Tregs)
in colorectal cancer (CRC) patients and
healthy controls. (A) The mean
ﬂuorescent intensity (MFI) of Foxp3
staining on CD3
+CD4
+CD25
hiFoxp3
+
and (B) total CD3
+CD4
+ Foxp3
+ PBL
was analysed by ﬂow cytometry using
peripheral blood samples obtained from
healthy controls and CRC patients
collected preoperatively.
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Colonwith metastatic melanoma, following administration of low-
dose interleukin-12.
25 26 We compared CD49d expression on
Tregs in CRC patients with those of healthy controls (ﬁgure 3F).
While we observed no overall difference in the expression level of
CD49d among the two groups (data not shown), the percentage
of CD4
+CD25
hiFoxp3
+ gated Tregs that expressed CD49d was
signiﬁcantly higher in patients than controls (p¼0.017),
implying that a greater proportion of Tregs in CRC patients are
able to migrate to sites of immune activity. Indeed, the majority
of tumour inﬁltrating CD4
+Foxp3
+ cells expressed CD49d
(ﬁgure 3G). We compared this to the expression of the integrin
CD103 (aEb7) which has also been associated with Tregs,
27
however very few tumour-inﬁltrating Tregs expressed this
marker (data not shown). Although we did not examine the
functional signiﬁcance of CD49d expression in our study, others
have reported that CD49d
+ Tregs exhibit a distinct phenotype.
28
The cells, which can be enriched through isolation of MHC class
II
+ Tregs, are potently suppressive in vitro, and furthermore can
induce secondary suppressor cells that produce the immuno-
suppressive cytokine, TGFb.
29 With these studies in mind, our
data further support the premise that Tregs derived from CRC
patients are more active than those in the control group.
Comparison of CD4
+Foxp3
+ T cells in patients following surgery
Foxp3 expression levels were compared in CRC patients preop-
eratively and at different time-points following surgical excision
of the tumour. This analysis revealed a signiﬁcant decline in
levels of Foxp3 expression by 12 weeks post-surgery (ﬁgure 4A,
Figure 3 Proportions of CD4 cells expressing Foxp3 in tumours and blood of colorectal cancer (CRC) patients. A representative example of a parafﬁn-
embedded human colorectal tumour triple-stained with Foxp3 (brown), CD8 (purple) and CD3 (grey) speciﬁc antibodies. CD4
+ cells are deﬁned as
those CD3 cells which do not stain for CD8 that is, they stain grey. The same area is shown at different magniﬁcations: (A) 403, (B) 1003, (C) 2003
and (D) 6003 ﬁnal magniﬁcation. Arrows show areas of tumour epithelium (stained weakly brown) and tumour stroma (unstained). The majority of T
cells including Foxp3
+ cells are found within the tumour stroma and sometimes Foxp3
+ T cells are seen in association with other T cells, as shown in
(D). (E) The percentage of CD4 cells expressing Foxp3 was determined in the tumours by immunohistochemistry (n¼67) and in the blood by ﬂow
cytometry (n¼17). Results are expressed as mean6SD. (F) Expression of CD49d on CD4
+CD25
hiFoxp3
+ cells from peripheral blood leucocytes of CRC
patients and healthy controls was analysed by ﬂow cytometry. (G) Representative example of CD49d expression on CD4
+Foxp3
+ tumour-inﬁltrating T
cells. PBMC, peripheral blood mononuclear cells; TIL, tumour-inﬁltrating lymphocyte.
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Colonp¼0.037; ﬁgure 4B, p¼0.0075) which was sustained over
a 12-month follow-up period and similar to Foxp3 expression in
controls. This pattern persisted when patients who received
postoperative chemotherapy were excluded from the analysis
(p<0.05). PBMCs from three healthy controls were examined
weekly for 12 weeks and Foxp3 expression levels compared at
a single time-point. No signiﬁcant ﬂuctuation was observed in
either individual over the entire period (Foxp3 MFI in three
individuals over nine separate time-points was 30.6462.3,
30.8461.8 and 30.6562). Since Foxp3 levels correlate with
suppressive capacity, the conclusion from these data is that the
tumour is inﬂuencing Treg activity.
CEA- and 5T4-speciﬁc CD4
+ T cell responses in CRC patients
pre- and post-surgery
Tumours utilise a variety of immunosuppressive strategies to
dampen effective anti-tumour immune responses.
30 To investi-
gate the impact of CRC on the immune system, we asked
whether removal of malignant bowel altered immune responses
to tumour antigens (CEA and 5T4) or control antigens (HA and
PPD). IFN-g-producing CD4
+ Tcells from PBMC were measured
ex-vivo by ELISpot in 58 patients preoperatively and in a follow-
up group at 3 months, 6 months and 12 months postoperatively.
We postulated that responses to the tumour-speciﬁc antigens,
measured postoperatively would be less subject to suppression
by Tregs than those measured preoperatively. To address this, all
ELISpot assays were set up at each time-point using whole
PBMC and PBMC depleted of CD25
hi cells. This approach
enabled us to determine whether responses were altered by
partial depletion of Tregs.
Use of the highly sensitive ELISpot assay enables accurate
identiﬁcation of low frequencies of antigen-speciﬁcC D 4
+ T
cells ex vivo.
17 21 This assay was used to measure responses to
5T4 and CEA antigens. A positive response was deﬁned by at
least 5 sfc per 10
6 PBMC, after subtraction of the background,
and an increase of at least 50% above background as described
previously.
21 The magnitude of the tumour antigen-speciﬁc
response ranged from 5 to 222 sfc/million PBMC. If the
response increased by at least 50% after depletion of Tregs
(CD25
hi cells), this was considered a positive effect of depletion.
Examples of 5T4- and CEA-speciﬁc responses in individual
patients are shown in ﬁgures 5A and 6A. The overall patterns of
responses to these tumour antigens, pre- and post-surgery are
shown in ﬁgures 5 and 6. There was a trend for an increase in
the percentage of patients responding postoperatively at 6 and
12 months to both tumour antigens (ﬁgures 5B and 6B). When
we compared only paired patient data at the preoperative and
the 6 month postoperative time-points, we found that neither
the magnitude of the CEA-speciﬁc responses (ﬁgure 5C) nor the
overall proportion of CEA responders (ﬁgure 5D) was signiﬁ-
cantly altered by surgery. In the case of CEA, around 50% of
responses were observed only after partial Treg depletion; this
proportion did not change signiﬁcantly after surgery (ﬁgure 5E).
This contrasts to the pattern of anti-tumour responses
measured using the tumour-speciﬁc antigen 5T4. The overall
number of responders increased after surgery (ﬁgure 6B) and
again when looking at paired data on subjects (ﬁgure 6D); the
magnitude of the responses increased along with the number of
responders (ﬁgure 6C). Interestingly, of the seven patients who
responded to 5T4 preoperatively, 5/7 (71%) of these responses
were observed only after partial depletion of Tregs. In contrast,
of the 14 patients who responded to 5T4 6 months after
surgery, suppression by Tregs was only observed in 7/14 (50%)
individuals (ﬁgure 6E), a pattern that showed no correlation
with chemotherapy. This observation implies that the
‘unmasking’ of responses to 5T4 observed after tumour resec-
tion can be attributed, at least in part, to a reduction in the
suppressive inﬂuence of Tregs. Overall, these data strongly
support the premise that the tumour is an inhibitory inﬂuence
on 5T4-speciﬁcr e s p o n s e s .
There was no evidence of generalised non-speciﬁc immuno-
suppression before surgery as 96% of the patients demonstrated
strong responses to one or both control antigens HA and PPD
preoperatively. In 19 patients with paired pre- and postoperative
data, there was a slight increase in responses to control antigens
in three of them (ﬁgure 7A,C). However, comparatively few
responses were actually unmasked after Treg depletion at any of
the time-points tested (ﬁgure 7B,D).
Comparison of 12-month tumour free survival with anti-tumour
immune responses
We addressed whether preoperative suppression of tumour
speciﬁc immune responses by Tregs was more likely to be
associated with tumour recurrence. Follow-up data were avail-
able on 44 patients who had reached the 12-month post-
operative time-point. Of these, 34 patients remained tumour
free (group A) while tumour recurrence was observed in 10
individuals (group B). As expected, recurrent disease did correlate
with the stage of disease at operation as all those with recurrent
disease at 12 months were diagnosed with Duke’s C or B
tumours. Anti-tumour CD4
+ T cell responses (5T4 and CEA)
were compared to control antigen CD4
+ T cell responses (PPD
and HA) preoperatively, and in particular whether these
responses were subject to suppression by Tregs (table 1).
Figure 4 Longitudinal analysis of
Foxp3 expression by regulatory T cells
(Tregs) in colorectal cancer (CRC)
patients. (A) The mean ﬂuorescent
intensity (MFI) of Foxp3 expressed on
CD3
+CD4
+CD25
hiFoxp3
+ and (B) total
CD3
+CD4
+Foxp3
+ peripheral blood
leucocytes (PBL) was analysed by ﬂow
cytometry on peripheral blood samples
obtained from healthy controls and CRC
patients collected preoperatively and at
12 weeks and 6 and 12 months
following surgery. Foxp3 expression of
cells in each CRC patient sample was
standardised to the mean Foxp3
expression observed in the control group.
Error bars represent SE of the mean.
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ColonIn both groups A and B there was no difference in responses to
control antigens or in the effects of suppression on these
responses. However, when the anti-tumour responses were
compared there is a clear difference between groups A and B. In
group A, which remained tumour-free at 12 months, 73% of
5T4- and 50% of CEA-speciﬁc responses were suppressed. In
contrast, in group B, 100% of responses that were measured to
either antigen were suppressed preoperatively (p¼0.003). Thus,
Figure 5 Analysis of longitudinal
ex-vivo carcinoembryonic antigen (CEA)
speciﬁc ELISpot responses by
colorectal cancer (CRC) patients.
Peripheral blood mononuclear cells
(PBMC) were puriﬁed from CRC
patients pre- and postoperatively.
Whole PBMC and regulatory T cell
(Treg) depleted PBMC were stimulated
with CEA and ex-vivo interferon-g
release was measured in an ELISpot
assay. (A) Examples of a non-responder
(patient 1), a responder (patient 71) and
a response that could only be detected
after depletion of CD4
+CD25
hi cells
(patient 11). C, control wells; Ag, CEA
containing wells; +Treg, undepleted
cultures; eTreg, cultures depleted of
CD4
+CD25
hi cells. (B) The total
percentage of patients that responded
to the antigen, including responses that
were either partially or completely
suppressed by Treg is displayed for
each time point. (C) The number of
CEA-speciﬁc sfc/10
6 PBMC observed
both preoperatively and 6 months after
surgery is shown as well as (D) the
percentage, and number, of patients, measured both pre- and 6-months postoperatively, responding to CEA. (E) Whole PBMC and Treg depleted PBMC
were stimulated with CEA and ex-vivo interferon-g release measured in ELISpot assays. The percentage of responses suppressed by Tregs is shown
for patients whose responses were measured both preoperatively and 6 months postoperatively.
Figure 6 Analysis of longitudinal
ex-vivo 5T4-speciﬁc ELISpot responses
by colorectal cancer (CRC) patients.
Peripheral blood mononuclear cells
(PBMC) were puriﬁed from CRC
patients pre- and postoperatively.
Whole PBMC and regulatory T cell
(Treg) depleted PBMC were stimulated
with 5T4 and ex-vivo interferon-g
release was measured in an ELISpot
assay. (A) Examples of a non-
responder, (patient 7), a responder
(patient 60) and a response that could
only be detected after depletion of
CD4
+CD25
hi cells (patient 11). C,
control wells; Ag, 5T4 containing wells;
+Treg, undepleted cultures;  Treg,
cultures depleted of CD4
+CD25
hi cells.
(B) The total percentage of patients that
responded to 5T4, including responses
that were either partially or completely
suppressed by Treg is displayed for
each time point. (C) The number of 5T4-
speciﬁc sfc/10
6 PBMC observed both
preoperatively and 6 months
postoperatively is shown as well as (D)
the percentage and number of patients,
measured both pre- and 6-month
postoperatively, responding to 5T4. (E)
The percentage of responses
suppressed by Tregs is shown for patients
whose responses were measured both
preoperatively and 6 months postoperatively.
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Colonwhile suppression of anti-tumour responses was observed in
both groups with no obvious correlation between tumour
suppression and tumour stage, the data nevertheless suggest
a close relationship between the presence of anti-tumour speciﬁc
Tregs and the recurrence of tumour at this time-point.
DISCUSSION
There is a need to improve treatment of CRC patients to reduce
the high rate of disease recurrence following potentially curative
surgery. In many cases malignant cells may seed other organs
and expand following surgery to cause patient death. Removing
these relatively small numbers of cells that remain after surgery
is difﬁcult and is currently only partially aided by postoperative
chemotherapy when indicated by histological staging of resected
malignant bowel. There is strong indirect evidence that T cells
can be effective at controlling CRC metastases.
1 How the
activity of these cells can be harnessed for the purpose of
immunotherapy is not yet understood. Indeed, several early
phase trials of vaccination in CRC have been disappointing,
31
possibly reﬂecting the persistence of regulatory mechanisms
which serve to down-modulate otherwise effective anti-tumour
immune responses.
The current study was undertaken to gain insight into the
impact of tumours on the immune response and in particular, on
Tregs. For this purpose we compared anti-tumour immune
responses and Tregs in patients pre- and postoperatively. This
longitudinal analysis revealed that Foxp3 expression levels are
higher in CRC patients compared to healthy controls and
strikingly, that in most subjects expression levels realign with
those observed in healthy controls, following tumour excision.
This ﬁnding may point to an effect of tumours in driving the
suppressive capacity of Tregs. In support of this premise,
detailed functional characterisation of Treg subsets and our own
ﬁndings (data not shown) indicate that Tregs expressing high
levels of Foxp3 have higher suppressive capacity than those
expressing lower levels.
23 Tumour recurrence was however
observed in some of the patients studied despite a decrease in
Foxp3 expression levels. Prior to surgery, the tumour represents
a large bulk of tissue that may have developed over several years,
leading to an increase in Tregs. On the other hand, relatively
small deposits of metastatic tissue may not lead to detectable
differences in Treg phenotype when assessed in whole PBMC.
Thus, in the case of disease recurrence, it may not be possible to
measure alterations in Tregs, particularly when detected at an
early stage such as 12 months postoperatively.
Our study also demonstrated that Treg proportions within
the CD4
+ Tcell population differ markedly in PBMCs compared
to tumour stroma. Data indicating that a signiﬁcantly higher
proportion of Foxp3
+ cells express CD49d in cancer patients
compared to healthy controls support this ﬁnding as CD49d
expression implies that the cells are actively migrating to a site
of immune activity. Deng et al, demonstrating a similar highly
signiﬁcant increase of Foxp3
+ cells in the tumour draining
lymph nodes and particularly the tumours of CRC patients
compared to PBMCs, corroborate these ﬁndings.
32 Overall, the
enrichment of Tregs within tumour-inﬁltrating leucocytes
strongly implies that this is an important site of tumour
immunosuppression.
Previous studies have documented 5T4- and CEA-speciﬁc
responses in CRC patients.
17 33 34 However, these studies did not
Figure 7 Analysis of longitudinal
ex-vivo haemagglutinin (HA) and
puriﬁed protein derivative (PPD) speciﬁc
ELISpot responses by colorectal cancer
(CRC) patients. Peripheral blood
mononuclear cells (PBMC) were
puriﬁed from CRC patients pre- and
postoperatively. Whole PBMC and
regulatory T cell (Treg) depleted PBMC
were stimulated with HA or PPD and
ex-vivo interferon-g release was
measured in an ELISpot assay. The total
percentage of patients that responded
to HA (A) or PPD (C) pre- and 6-months
postoperatively are shown. The
percentage of HA (B) and PPD speciﬁc
(D) responses completely unmasked by
Tregs is shown for patients whose
responses were measured both
preoperatively and 6 months postoperatively.
Table 1 Regulatory T cell (Treg) suppression of ex-vivo interferon
(IFN)-g responses to tumour antigens and 12-month tumour status
Preoperative ELISpot responses
Group A Group B
Tumour free
(n[34)
Tumour recurred
(n[10)
Total PPD-speciﬁc responses 91% 100%
31/34 10/10
Suppressed PPD responses 65% 60%
20/31 6/10
Total HA-speciﬁc responses 74% 80%
25/34 8/10
Suppressed HA responses 64% 50%
16/26 4/8
Total 5T4-speciﬁc responses 44% 40%
15/34 4/10
Suppressed 5T4 responses 73% 100%
11/15 4/4
Total CEA-speciﬁc responses 41% 70%
14/34 7/10
Suppressed CEA responses 50% 100%
7/14 7/7
Ex-vivo IFN-g responses to control antigens (PPD and HA) and the tumour antigens (5T4
and CEA) by whole and Treg depleted peripheral blood mononuclear cells was determined
by ELISpot. The number and proportion of patients that made a response and whether the
response was suppressed by Tregs is shown. Data are shown for 44 patients for whom
12 month clinical outcome data were available.
CEA, carcinoembryonic antigen; HA, haemagglutinin; PPD, puriﬁed protein derivative.
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Colontake the effect of surgery into account. Thus, the second part of
this study examined longitudinal effector T cell responses to
CEA and 5T4 pre- and postoperatively and measured the impact
of Tregs on these responses at the same time-points. The data
demonstrate that at least two thirds of patients studied
responded to one or both of the antigens under study but that
Tregs suppressed these responses in the majority of cases. When
the preoperative 5T4-speciﬁc responses of individual patients
were compared to responses 6 months after surgery, a signiﬁcant
elevation of 5T4 responses was observed at the latter time-point,
suggesting that removal of the tumour burden facilitates the
unmasking of a previously suppressed CD4
+ Tcell response. Our
data imply that Tregs are at least partly responsible for this
suppression as a lower proportion of 5T4-speciﬁc responses were
suppressed postoperatively. Overall these data support the
earlier ﬁndings of the study, which indicate that tumours
expand the Treg population, driving suppression of CD4
+ Tcell
responses to tumour-associated antigens. Furthermore, the
results offer some insight into Treg speciﬁcity. Since suppression
was assessed in assays using 5T4 (and CEA) pulsed PBMCs as
stimulators, it suggests that both the effector cells and the Tregs
recognise the same protein antigen. The pattern of responses to
CEA was similar to 5T4. However, the extent to which Tregs
suppressed CEA responses did not alter after surgery. It is
possible that CEA-speciﬁc Tregs are maintained by inﬂuences
other than the tumour for the purpose of limiting self-reactivity
in the healthy host, as CEA, unlike 5T4, is expressed at low
levels in normal tissue. While some degree of non-speciﬁc
immunosuppression was detected, overall the data indicate that
the greatest extent of suppression is observed when measuring
responses to tumour antigens.
An extremely important aspect of this study is the absolute
concordance of tumour recurrence at a 12-month postoperative
time-point and Treg-mediated suppression of CEA- and 5T4-
speciﬁc responses, measured preoperatively. No such concordance
was observed within the group of patients remaining tumour-free
or with respect to Treg mediated suppression of responses to
unrelated control antigens. Recent studies have however, reported
that high numbers of intratumoural Foxp3
+ Tcells are associated
with better survival of CRC patients.
18 35 More than one expla-
nation can account for these seemingly contradictory ﬁndings.
The role of Tregs may depend on the type of immune response
present in the tumour microenvironment. When inﬂammatory
cells that promote tumour progression dominate the immune
response, Tregs may be beneﬁcial in suppressing this process.
36
However, in the case where the immune response is dominated
by Tcells, Tregs may promote disease progression by suppressing
their anti-tumour effects. More simplistically, Treg numbers may
accumulate in parallel with the conventional Tcell response, thus
their presence could just reﬂect robust anti-tumour Tcell activity
known to correlate with an improved prognosis.
1 The data
presented here underpin the importance of conducting further
studies of CRC patients to include more antigens and larger
patient groups in order to identify Tcell speciﬁcities involved in
controlling tumour growth and those that might be involved in
promoting tumour growth. A better understanding of the rela-
tionship between tumours and Tregs may prove instrumental to
the success of anticancer immunotherapy.
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